Sean Clayton Biography and Net Worth

Sean Clayton joined Horizon in February 2022 and has nearly 20 years of experience representing public and private biotechnology companies in general corporate matters and securities laws, as well as a wide range of transactions, including public and private financings. Before joining Horizon, Sean served as a partner at Cooley LLP where he led the firm’s San Diego corporate practice. He led the Cooley team that represented Horizon in its initial public offering in 2011 and subsequently advised Horizon’s management team and board of directors on corporate and transactional matters.

Sean received his doctorate in jurisprudence from Stanford Law School and his Bachelor of Arts in political science and economics from the University of California, San Diego.

What is Sean M. Clayton's net worth?: The estimated net worth of Sean M. Clayton is at least $86,643.50 as of August 4th, 2022. Mr. Clayton owns 745 shares of Horizon Therapeutics Public stock worth more than $86,644 as of November 15th. This net worth estimate does not reflect any other investments that Mr. Clayton may own. Additionally, Mr. Clayton receives an annual salary of $7,030,000.00 as EVP at Horizon Therapeutics Public. Learn More about Sean M. Clayton's net worth.
How old is Sean M. Clayton?: Mr. Clayton is currently 44 years old. There are 5 older executives and no younger executives at Horizon Therapeutics Public. Learn More on Sean M. Clayton's age.
What is Sean M. Clayton's salary?: As the EVP of Horizon Therapeutics Public Limited, Mr. Clayton earns $7,030,000.00 per year. Learn More on Sean M. Clayton's salary.
How do I contact Sean M. Clayton?: The corporate mailing address for Mr. Clayton and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Sean M. Clayton's contact information.
Has Sean M. Clayton been buying or selling shares of Horizon Therapeutics Public?: Sean M. Clayton has not been actively trading shares of Horizon Therapeutics Public during the last quarter. Most recently, on Thursday, August 4th, Sean M. Clayton bought 745 shares of Horizon Therapeutics Public stock. The stock was acquired at an average cost of $66.67 per share, with a total value of $49,669.15. Following the completion of the transaction, the executive vice president now directly owns 745 shares of the company's stock, valued at $49,669.15. Learn More on Sean M. Clayton's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Sean M. Clayton Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/4/2022	Buy	745	$66.67	$49,669.15	745

Sean M. Clayton Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03

Top "Sleeping Giant" Crypto In The Market Now

From Crypto 101 Media | Ad

Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future.

Click here to discover our #1 crypto pick before it's too late

Sean Clayton Biography and Net Worth

What is Sean M. Clayton's net worth?

How old is Sean M. Clayton?

What is Sean M. Clayton's salary?

How do I contact Sean M. Clayton?

Has Sean M. Clayton been buying or selling shares of Horizon Therapeutics Public?

Who are Horizon Therapeutics Public's active insiders?